Rexahn Pharmaceuticals (RNN) Trading Down 29.3%

Rexahn Pharmaceuticals, Inc. (NYSEAMERICAN:RNN) was down 29.3% on Wednesday . The company traded as low as $1.14 and last traded at $1.18. Approximately 2,694,748 shares were traded during mid-day trading, an increase of 885% from the average daily volume of 273,630 shares. The stock had previously closed at $1.67.

A number of equities research analysts have weighed in on RNN shares. HC Wainwright set a $20.00 price target on shares of Rexahn Pharmaceuticals and gave the company a “buy” rating in a report on Tuesday, September 25th. B. Riley set a $8.00 price target on shares of Rexahn Pharmaceuticals and gave the company a “buy” rating in a report on Monday, August 13th. Ifs Securities raised shares of Rexahn Pharmaceuticals from an “outperform” rating to a “strong-buy” rating in a research note on Thursday, October 4th. Finally, Zacks Investment Research raised shares of Rexahn Pharmaceuticals from a “hold” rating to a “buy” rating and set a $1.75 price objective for the company in a research note on Friday, August 10th. One investment analyst has rated the stock with a sell rating, one has given a hold rating, two have given a buy rating and one has issued a strong buy rating to the company. The stock presently has an average rating of “Buy” and a consensus price target of $9.92.

Rexahn Pharmaceuticals (NYSEAMERICAN:RNN) last posted its quarterly earnings data on Monday, August 6th. The company reported ($0.15) EPS for the quarter, beating analysts’ consensus estimates of ($0.18) by $0.03.

An institutional investor recently raised its position in Rexahn Pharmaceuticals stock. Northern Trust Corp grew its holdings in Rexahn Pharmaceuticals, Inc. (NYSEAMERICAN:RNN) by 61.3% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 77,213 shares of the company’s stock after purchasing an additional 29,354 shares during the period. Northern Trust Corp owned about 0.24% of Rexahn Pharmaceuticals worth $117,000 as of its most recent SEC filing.

Rexahn Pharmaceuticals Company Profile (NYSEAMERICAN:RNN)

Rexahn Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, discovers, develops, and commercializes treatments for cancer. The company's clinical stage drug candidates include RX-3117, which is in Phase II a clinical trial for the treatment of patients with relapsed or refractory pancreatic cancer and advanced bladder cancer; and Supinoxin that is in Phase II a clinical study to treat patients with metastatic triple negative breast cancer.

Featured Story: Discover Your Risk Tolerance

Receive News & Ratings for Rexahn Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rexahn Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply